To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

NCT06389006 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Disitamab Vedotin for Injection
DRUG: Toripalimab
DRUG: Epirubicin
DRUG: Cyclophosphamide

Sponsor

RemeGen Co., Ltd.